Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for... Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs Edward A. Berger Laboratory of Viral Diseases, National Institute of Purpose of review Allergy and Infectious Diseases, National Institutes of HIV-infected cells persisting in the face of highly active antiretroviral therapy are Health, Bethesda, Maryland, USA arguably the greatest hurdle to eradication of the virus from the body. Complementary Correspondence to Edward A. Berger, Laboratory of strategies aimed at selective killing of infected cells are described. Viral Diseases, NIAID, National Institutes of Health, Building 33, Room 3W20, Bethesda, MD 20892, USA Recent findings Tel: +1 301 402 2481; fax: +1 301 435 1269; Pioneered by research in the cancer field, various approaches are under development e-mail: edward_berger@nih.gov for selective killing of HIV-infected cells. These include targeted cytotoxic proteins, Current Opinion in HIV and AIDS 2011, adoptive cell therapy, cytocidal virotherapy, and targeted nonbiological drug carriers. 6:80–85 Summary These developmental efforts may provide a critical complement to antiretroviral therapy in efforts to achieve HIV eradication, or a ‘functional cure’ whereby therapy can be stopped without viral rebound. Keywords adoptive cell therapy, antibody–drug conjugates, chimeric antigen receptor, immunotoxin, oncolytic virotherapy, radioimmunotherapy, targeted liposome Curr Opin http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs

Berger, Edward A
Current Opinion in HIV and Aids , Volume 6 (1) – Jan 1, 2011
Download PDF
6 pages

Loading next page...
 
/lp/wolters-kluwer-health/targeted-cytotoxic-therapy-colon-adapting-a-rapidly-progressing-I0whhhzozt

References (52)

ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0b013e3283412515
pmid
21242898
Publisher site
See Article on Publisher Site

Abstract

Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs Edward A. Berger Laboratory of Viral Diseases, National Institute of Purpose of review Allergy and Infectious Diseases, National Institutes of HIV-infected cells persisting in the face of highly active antiretroviral therapy are Health, Bethesda, Maryland, USA arguably the greatest hurdle to eradication of the virus from the body. Complementary Correspondence to Edward A. Berger, Laboratory of strategies aimed at selective killing of infected cells are described. Viral Diseases, NIAID, National Institutes of Health, Building 33, Room 3W20, Bethesda, MD 20892, USA Recent findings Tel: +1 301 402 2481; fax: +1 301 435 1269; Pioneered by research in the cancer field, various approaches are under development e-mail: edward_berger@nih.gov for selective killing of HIV-infected cells. These include targeted cytotoxic proteins, Current Opinion in HIV and AIDS 2011, adoptive cell therapy, cytocidal virotherapy, and targeted nonbiological drug carriers. 6:80–85 Summary These developmental efforts may provide a critical complement to antiretroviral therapy in efforts to achieve HIV eradication, or a ‘functional cure’ whereby therapy can be stopped without viral rebound. Keywords adoptive cell therapy, antibody–drug conjugates, chimeric antigen receptor, immunotoxin, oncolytic virotherapy, radioimmunotherapy, targeted liposome Curr Opin

Journal

Current Opinion in HIV and Aids – Wolters Kluwer Health

Published: Jan 1, 2011

There are no references for this article.